News

Get Alerts by Email

Dec 17, 2020

Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021

New Phase 1 Data Confirm Aramchol Meglumine PK Parameters Similar to Aramchol Acid

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an...
- Photos 1
Nov 12, 2020

Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results

- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an...
- Photos 1
Nov 9, 2020

Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol

Collaboration Seeks to Enhance Response Rate and Identify Biomarker for Treatment of NASH and Fibrosis

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement to identify and optimize the selected...
- Photos 2
Nov 5, 2020

Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator,...
- Photos 1
Sep 10, 2020

Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement...
- Photos 1

Show per page